Pharmaceutical companies with recently commercialized products can often be promising investment opportunities. One such company that has recently launched a new treatment option is Ironwood Pharmaceuticals (IRWD). Ironwood Pharmaceuticals is a developing company looking to lead in the field of gastrointestinal therapeutics. The company is expanding the scientific frontier due to its pharmacologic expertise in guanylate cyclate pathways. The company is looking to introduce a new class of gastrointestinal medicines called GC-C agonists.
Ironwood's two most advanced GC-C agonists include "Linaclotide" and "IW-9179". In August 2012, Linaclotide gained approval from the U.S. Food and Drug Administration, allowing it to be sold under the trade name of Linzess. IW-9179 is a GC-C agonist designed to target upper...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|